

REMARKS

Claims 27-41 are pending in this application.

In further support of Applicants arguments presented in the Response and Request for Reconsideration mailed 12/19/07, Applicants respectfully submit herewith a declaration by the inventors that further demonstrates that claims 27-41 are enabled. In this declaration, the inventors provide the basic protocol for the MLR assay as well as copies of pages from an internal database showing the positive results for the PRO361 polypeptide in the MLR assay. The assay data shown in Exhibit A indicates that the PRO361 polypeptide inhibits T-cell proliferation in the MLR assay and provides further evidence that one of ordinary skill in the art would have been able to make and use the claimed nucleic acids for the intended purpose (immune suppression) without undue experimentation. Applicants respectfully maintain their request that the enablement rejection of Claims 27-41 under 35 U.S.C. § 112, first paragraph, be withdrawn.

CONCLUSION

Applicants respectfully request the Examiner grant allowance of pending claims 27-41. The Examiner is invited to contact the undersigned attorney for the Applicant via telephone if such communication would expedite allowance of this application.

Respectfully submitted,



C. Noel Kaman
Registration No. 51,857
Attorney for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200